nirmatrelvir/ritonavir (Paxlovid) | Drugs Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,162 results for “nirmatrelvir/ritonavir (Paxlovid)”

Nirmatrelvir(Paxlovid)

Conditions: Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)

C₂₃H₃₂F₃N₅O₄

Deuterated-Nirmatrelvir

PF-07321332 + ritonavir

Ritonavir(Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan, Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan), Ritonavir Viatris (previously Ritonavir Mylan), Viekirax)

Manufacturer: Abbott laboratories pharmaceutical products div, Abbott laboratories

Conditions: Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b +2 more

C₃₇H₄₈N₆O₅S₂ · Rx

Simnotrelvir/Ritonavir

Lopinavir/Ritonavir

Atilotrelvir/Ritonavir

elvitegravir;ritonavir

morphothiadine + ritonavir

darunavir + ritonavir

Page 1 of 9